SwanBio Therapeutics

We are excited to share that SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com. 

Of the 6000+ known rare diseases, why was SwanBio founded to focus on AMN? Listen & learn as we strive to every day – and especially today, #RareDiseaseDay.   We are indebted to the adrenomyeloneuropathy community for the trust and faith they have put in our team to develop the first clinical-stage gene therapy for this devastating disease. We constantly strive to better understand the impact of AMN on patients, caregivers, and families in order to make a meaningful difference.   #RDD2024

We’re getting ready to honor #RareDiseaseDay later this month with a conversation between our co-founders about WHY.   Why does SwanBio exist? Why are we so committed to developing a gene therapy for #AMN? Why is drug development for rare diseases so different than more common conditions?   Thank you Florian Eichler for joining us to remind us that 'rare' does not mean different, separate, or alone. #showyourstripes #adrenomyeloneuropathy #RDD24

This Thurs, Feb 15: Our Co-Founder and CSO Karen Kozarsky, Ph.D. will join other industry leaders to discuss #genetherapy manufacturing. Register below!

We kicked off February by gathering some of our Swans to celebrate our 6th birthday. Thank you to our extended Pond who has supported us along the way: our team members, research partners, clinicians, clinical trial sites, and members of the AMN community. We are incredibly proud of what we've learned about #adrenomyeloneuropathy and AAV #genetherapy over the past 6 years, with your collaboration and shared insights. Cheers to many more!

Our CSO Karen Kozarsky, Ph.D. is pleased to be joining other industry experts next month (Thurs, Feb 15) to discuss #genetherapy manufacturing. Register today!

Don’t miss our must-see webinar with Endpoints News featuring notable industry leaders to discuss “7 questions gene therapy developers should ask their CDMO (and what they will ask you!)" We’ll delve into the key questions around yield, commercial readiness, validated scale-down models, automation of analytical assays, and more. Speakers: David Dismuke Jenny Holt Karen Kozarsky, Ph.D. John Maslowski Register here ➡️ https://hubs.li/Q02gjHZp0

While we welcome new leaders to the Pond this week, we are also taking the time to thank & recognize Thomas D. Anderson for his steadfast leadership. With Topher Brooke stepping in as our new COO, Tom will be moving from his position as CEO into a strategic advisor role, and maintaining his seat on our Board. Tom's poised and humble leadership have set the tone for our culture and core values over the past four years. His spirit of collaboration has led our team through multiple key accomplishments, including - most recently - the initiation of our higher-dose cohort in the study of our gene therapy for #AMN, following a recommendation from the DSMB. Thank you, Tom! And see you soon. #genetherapy #adrenomyeloneuropathy #CEOoftheyear